ASX:PXS Pharmaxis (PXS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Pharmaxis Stock (ASX:PXS) Get Pharmaxis alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume721,139 shsAverage VolumeN/AMarket CapitalizationA$20.23 millionP/E RatioN/ADividend Yield6.41%Price TargetN/AConsensus RatingN/A Company Overview Pharmaxis Ltd, a clinical stage drug development company, engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. It operates through Mannitol Respiratory Business and New Drug Development segments. The company provides Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test for the treatment of asthma. It's product pipeline comprises oral pan-Lysyl Oxidase Inhibitors (LOX) targeting myelofibrosis and other cancers; topical pan-LOX inhibitors targeting skin scarring after events such as accidents, surgery, and burns; selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic diseases including kidney, pulmonary, liver, and cardiac fibrosis; and semicarbazide-sensitive amine oxidase for neuro inflammatory diseases. The company also offers Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia. Read More Receive PXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharmaxis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PXS Stock News HeadlinesPharmaxis Ltd Highlights Strategic Initiatives at Healthcare ConferenceSeptember 8, 2025 | tipranks.comPharmaxis Ltd Releases Annual Financial Report for 2025August 28, 2025 | tipranks.comElon callingElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corporate history. Tesla insiders are preparing for a dramatic new product launch – not driverless cars – that could change everything. You're running out of time to prepare. | Altimetry (Ad)Pharmaxis Ltd Discusses Syntara’s Future Prospects and RisksAugust 18, 2025 | tipranks.comCanaccord Genuity Sticks to Their Buy Rating for Pharmaxis Ltd (SNT)March 14, 2025 | markets.businessinsider.comPharmaxis Ltd Highlights Product Pipeline and RisksOctober 30, 2024 | markets.businessinsider.comSyntara bolsters financial position with R&D tax incentiveDecember 4, 2023 | proactiveinvestors.com.auHere's Why Shareholders Should Examine Pharmaxis Ltd's (ASX:PXS) CEO Compensation Package More CloselyNovember 21, 2023 | finance.yahoo.comSee More Headlines PXS Stock Analysis - Frequently Asked Questions How were Pharmaxis' earnings last quarter? Pharmaxis Ltd (ASX:PXS) posted its earnings results on Thursday, February, 14th. The company reported ($0.03) earnings per share (EPS) for the quarter. Pharmaxis had a negative trailing twelve-month return on equity of 143.13% and a negative net margin of 161.24%. What other stocks do shareholders of Pharmaxis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pharmaxis investors own include Atara Biotherapeutics (ATRA), CRISPR Therapeutics (CRSP), Acasti Pharma (ACST), American Woodmark (AMWD), Guardion Health Sciences (GHSI), Incannex Healthcare (IHL) and XPO (XPO). Company Calendar Last Earnings2/14/2019Today10/09/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryTransportation Current SymbolASX:PXS CIKN/A Webwww.pharmaxis.com.au Phone+61-2-94547200FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth0.21Net Income-A$18.43 million Net Margins-161.24% Pretax MarginN/A Return on Equity-143.13% Return on Assets-48.68% Debt Debt-to-Equity RatioN/A Current Ratio7.21 Quick Ratio14.73 Sales & Book Value Annual SalesA$11.89 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.32 Book ValueA$0.00 per share Price / BookN/AMiscellaneous Outstanding Shares722,610,000Free FloatN/AMarket CapA$20.23 million OptionableNot Optionable Beta0.64 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (ASX:PXS) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network...The Oxford Club | SponsoredElon callingElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | SponsoredNvidia and AMD just surged. But this setup was already winning.Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a sin...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharmaxis Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharmaxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.